2022
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet 2022, 400: 896-907. PMID: 36116480, DOI: 10.1016/s0140-6736(22)01475-1.Peer-Reviewed Original ResearchConceptsHeavy menstrual bleedingPhase 3 trialSymptomatic uterine fibroidsMenstrual bleedingUterine fibroidsTherapy groupPlacebo groupOral gonadotropin-releasing hormone receptor antagonistResponse rateGonadotropin-releasing hormone receptor antagonistCommon adverse eventsFull analysis setHormone receptor antagonistDose of treatmentMasked treatmentPrimary endpointStudy drugAdverse eventsEligible womenHot flushesChronic treatmentReceptor antagonistGonadal steroidsLinzagolixAnalysis set
2021
Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients
Abrao MS, Surrey E, Gordon K, Snabes MC, Wang H, Ijacu H, Taylor HS. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients. BMC Women's Health 2021, 21: 246. PMID: 34134684, PMCID: PMC8210385, DOI: 10.1186/s12905-021-01385-3.Peer-Reviewed Original ResearchConceptsNon-menstrual pelvic painEndometriosis-associated painBaseline characteristicsSubgroup interactionsEndometriosis Health Profile-30Severe endometriosis-associated painGonadotropin-releasing hormone receptor antagonistEfficacy of elagolixPatient-reported reductionsPhase 3 studyHealth-related qualityReal-world patientsHormone receptor antagonistSubgroup of womenSignificant treatmentPercentage of womenAnalgesic usePelvic painMonth 3Receptor antagonistPrevious historyMost subgroupsPainPatient typesEndometriosis disease
2020
A Clinician's Guide to the Treatment of Endometriosis with Elagolix
Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS. A Clinician's Guide to the Treatment of Endometriosis with Elagolix. Journal Of Women's Health 2020, 30: 569-578. PMID: 32975461, PMCID: PMC8064963, DOI: 10.1089/jwh.2019.8096.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painQuality of lifeGonadotropin-releasing hormone receptor antagonistBaseline clinical factorsModulation of estradiolIntolerable side effectsNew oral therapiesTreatment of endometriosisAvailable treatment optionsHormone receptor antagonistIndividualization of treatmentHypoestrogenic effectsRescue analgesicsPelvic painGnRH agonistOral therapyClinical factorsPain managementClinical evidenceTreatment optionsDosing optionsReceptor antagonistInsufficient efficacyClinician's GuideSide effectsElagolix in the treatment of endometriosis: impact beyond pain symptoms
Archer DF, Soliman AM, Agarwal SK, Taylor HS. Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances In Reproductive Health 2020, 14: 2633494120964517. PMID: 33294846, PMCID: PMC7708701, DOI: 10.1177/2633494120964517.Peer-Reviewed Original ResearchPain symptomsSystemic manifestationsOral gonadotropin-releasing hormone receptor antagonistGonadotropin-releasing hormone receptor antagonistTreatment of endometriosisHormone receptor antagonistQuality of lifePelvic painSevere painCommon symptomsReceptor antagonistEndometriosisElagolixBeneficial effectsSymptomsPainManifestationsOutcomesPatientsWorkplace effectsAntagonistDiseaseWomen
2015
Prostate Cancer‐Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
Ong SY, Taverna J, Jokerst C, Enzler T, Hammode E, Rogowitz E, Green MR, Babiker HM. Prostate Cancer‐Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix. Case Reports In Oncological Medicine 2015, 2015: 212543. PMID: 26613055, PMCID: PMC4646996, DOI: 10.1155/2015/212543.Peer-Reviewed Original ResearchDisseminated intravascular coagulationProstate cancerIntravascular coagulationExcessive fibrinolysisGonadotropin-releasing hormone receptor antagonistTherapeutic drug optionsHormone receptor antagonistLife-threatening variantDays of treatmentHemorrhagic complicationsSystemic bleedingDrug optionsReceptor antagonistPatient's coagulopathySingle injectionCoagulopathyDegarelixPatientsFibrinolysisCancerCoagulationBleedingComplicationsAntagonistHypofibrinogenemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply